Rhythm Pharmaceuticals, Inc. (RYTM)
| Previous close | 38.15 |
| Open | 38.39 |
| Bid | 38.26 x 100 |
| Ask | 38.66 x 100 |
| Day's range | 37.40 - 38.89 |
| 52-week range | 15.50 - 52.57 |
| Volume | |
| Avg. volume | 578,332 |
| Market cap | 2.312B |
| Beta (5Y monthly) | 1.93 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.20 |
| Earnings date | 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 59.00 |
GlobeNewswireRhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, May 7, 2024 to report its first quarter 2024 financial results and provide a corporate update. To access the live conference call, participants may register here.
- GlobeNewswire
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
BOSTON, April 16, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that on April 11, 2024, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 31,220 shares of its common stock to eight new employees, consisting of inducement stock options to purc
Simply Wall St.Market Sentiment Around Loss-Making Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
Rhythm Pharmaceuticals, Inc. ( NASDAQ:RYTM ) is possibly approaching a major achievement in its business, so we would...
